FY2024 EPS Estimate for Disc Medicine Increased by Analyst

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Lifesci Capital raised their FY2024 earnings per share (EPS) estimates for shares of Disc Medicine in a report released on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($3.92) for the year, up from their previous forecast of ($4.33). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. Lifesci Capital also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.94) EPS.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15.

A number of other research analysts have also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Jefferies Financial Group began coverage on Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective on the stock. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a research note on Tuesday, November 5th. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $83.00 price objective (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Disc Medicine currently has an average rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Price Performance

Shares of NASDAQ:IRON opened at $60.67 on Friday. The company’s fifty day moving average price is $51.02 and its 200-day moving average price is $44.75. Disc Medicine has a one year low of $25.60 and a one year high of $77.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in IRON. Amalgamated Bank boosted its position in shares of Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Disc Medicine by 2.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after purchasing an additional 771 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Disc Medicine by 19.5% in the third quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after purchasing an additional 793 shares during the last quarter. Finally, Bleakley Financial Group LLC lifted its holdings in shares of Disc Medicine by 23.0% during the first quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock valued at $285,000 after purchasing an additional 856 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Buying and Selling

In related news, Director William Richard White sold 7,136 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 7,538 shares of company stock valued at $437,875 over the last quarter. 4.24% of the stock is owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.